NASDAQ

Ernexa Therapeutics Inc. - Warrants (ERNAW)

467 Thanks from members

Ernexa Therapeutics Warrants (ERNAW) reflect volatile micro-cap biotechnology sentiment, tracking the common stock (ERNA) as the company approaches its critical Q3 2026 IND submission for its lead cell therapy candidate, ERNA-101.

No chart available for this instrument.
Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →